Dow Up0.12% Nasdaq Up1.35%

Cardiome Pharma Corp. (CRME)

7.61 0.20(2.56%) Oct 20, 4:00PM EDT
ProfileGet Profile for:
Cardiome Pharma Corp.
6190 Agronomy Road
Suite 405
Vancouver, BC V6T 1Z3
Canada - Map
Phone: 604-677-6905
Fax: 604-677-6915

Index Membership:N/A
Industry:Drug Manufacturers - Other
Full Time Employees:75

Business Summary 

Cardiome Pharma Corp., a biopharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies that enhance the life and health of patients. It offers BRINAVESS (vernakalant IV), for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company’s pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Cardiome Pharma Corp.

Key Executives 
Dr. William L. Hunter M.D., BSc, 51
Chief Exec. Officer, Pres and Director
Ms. Jennifer Archibald CA,
Chief Financial Officer
Ms. Sheila M. Grant MBA,
Chief Operating Officer
Mr. David D. McMasters Esq., 55
Corp. Gen. Counsel
Mr. Karim Lalji MS, SM,
Chief Commercial Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders